Innate immune cells, particularly macrophages and epithelial cells, play a key role in multiple layers of immune responses. Alarmins and pro-inflammatory cytokines from the IL (interleukin)-1 and TNF (tumour necrosis factor) families initiate the cascade of events by inducing chemokine release from bystander cells and by the up-regulation of adhesion molecules required for transendothelial trafficking of immune cells. Furthermore, innate cytokines produced by dendritic cells, macrophages, epithelial cells and innate lymphoid cells seem to play a critical role in polarization of helper T-cell cytokine profiles into specific subsets of Th1/Th2/Th17 effector cells or regulatory T-cells. Lastly, the innate immune system down-regulates effector mechanisms and restores homoeostasis in injured tissue via cytokines from the IL-10 and TGF (transforming growth factor) families mainly released from macrophages, preferentially the M2 subset, which have a capacity to induce regulatory T-cells, inhibit the production of pro-inflammatory cytokines and induce healing of the tissue by regulating extracellular matrix protein deposition and angiogenesis. Cytokines produced by innate immune cells represent an attractive target for therapeutic intervention, and multiple molecules are currently being tested clinically in patients with inflammatory bowel disease, rheumatoid arthritis, systemic diseases, autoinflammatory syndromes, fibrosing processes or malignancies. In addition to the already widely used blockers of TNFα and the tested inhibitors of IL-1 and IL-6, multiple therapeutic molecules are currently in clinical trials targeting TNF-related molecules [APRIL (a proliferation-inducing ligand) and BAFF (B-cell-activating factor belonging to the TNF family)], chemokine receptors, IL-17, TGFβ and other cytokines.

000      

00000naa a2200000 a 4500

001      

bmc14050699

003      

CZ-PrNML

005      

20170405072432.0

007      

ta

008      

140401s2014 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1042/CS20130497 $2 doi

035    __

$a (PubMed)24450743

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Striz, Ilja

245    10

$a Cytokine networking of innate immunity cells: a potential target of therapy / $c I. Striz, E. Brabcova, L. Kolesar, A. Sekerkova,

520    9_

$a Innate immune cells, particularly macrophages and epithelial cells, play a key role in multiple layers of immune responses. Alarmins and pro-inflammatory cytokines from the IL (interleukin)-1 and TNF (tumour necrosis factor) families initiate the cascade of events by inducing chemokine release from bystander cells and by the up-regulation of adhesion molecules required for transendothelial trafficking of immune cells. Furthermore, innate cytokines produced by dendritic cells, macrophages, epithelial cells and innate lymphoid cells seem to play a critical role in polarization of helper T-cell cytokine profiles into specific subsets of Th1/Th2/Th17 effector cells or regulatory T-cells. Lastly, the innate immune system down-regulates effector mechanisms and restores homoeostasis in injured tissue via cytokines from the IL-10 and TGF (transforming growth factor) families mainly released from macrophages, preferentially the M2 subset, which have a capacity to induce regulatory T-cells, inhibit the production of pro-inflammatory cytokines and induce healing of the tissue by regulating extracellular matrix protein deposition and angiogenesis. Cytokines produced by innate immune cells represent an attractive target for therapeutic intervention, and multiple molecules are currently being tested clinically in patients with inflammatory bowel disease, rheumatoid arthritis, systemic diseases, autoinflammatory syndromes, fibrosing processes or malignancies. In addition to the already widely used blockers of TNFα and the tested inhibitors of IL-1 and IL-6, multiple therapeutic molecules are currently in clinical trials targeting TNF-related molecules [APRIL (a proliferation-inducing ligand) and BAFF (B-cell-activating factor belonging to the TNF family)], chemokine receptors, IL-17, TGFβ and other cytokines.

650    _2

$a adaptivní imunita $7 D056704

650    _2

$a zvířata $7 D000818

650    _2

$a antiflogistika $x terapeutické užití $7 D000893

650    _2

$a antitumorózní látky $x terapeutické užití $7 D000970

650    _2

$a cytokiny $x metabolismus $7 D016207

650    _2

$a lidé $7 D006801

650    _2

$a imunitní systém $x účinky léků $x imunologie $7 D007107

650    12

$a přirozená imunita $x účinky léků $7 D007113

650    _2

$a imunosupresiva $x terapeutické užití $7 D007166

650    _2

$a mediátory zánětu $x metabolismus $7 D018836

650    12

$a signální transdukce $x účinky léků $7 D015398

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Brabcová, Eva $u - $7 xx0212445

700    1_

$a Kolesar, Libor $u -

700    1_

$a Sekerkova, Alena $u -

773    0_

$w MED00009494 $t Clinical science (London, England 1979) $x 1470-8736 $g Roč. 126, č. 9 (2014), s. 593-612

856    41

$u https://pubmed.ncbi.nlm.nih.gov/24450743 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20140401 $b ABA008

991    __

$a 20170405072723 $b ABA008

999    __

$a ok $b bmc $g 1017835 $s 849279

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2014 $b 126 $c 9 $d 593-612 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494

LZP    __

$a Pubmed-20140401